What Uni-Med LLC does

Uni-Med LLC (ООО «Уни-мед») is a privately held Russian medical laboratory headquartered in Moscow at ul. Piryeva, dom 11A, that specializes in biochemical diagnostic services for assessing human microbiome status. The company operates a horizontally segmented business that serves patient end-users (primarily those with gastrointestinal disorders and dental patients with gingivitis, periodontitis, or caries) and B2B customers (medical laboratories and practicing physicians) through a partner network that includes KDL, Citilab, Helix, Gemotest, and corporate clinics such as the Polyclinic of Gazprom JSC. Uni-Med holds a Medical Activity License from the Moscow Department of Health covering laboratory diagnostics and clinical laboratory diagnostics, and it is the registrant of an approved Russian medical technology (Registration Certificate FS-2006/030-u, dated 17.03.2006).

The company's core technology is a proprietary gas-liquid chromatography method for determining short-chain fatty acids (SCFAs, C2-C6 fractions with isomers) in biological substrates such as stool and saliva. Two flagship services flow from this platform: a biochemical express analysis of fecal metabolites for dysbiosis assessment, with results available within approximately one hour, and a biochemical express analysis of oral fluid for oral microbiome evaluation, with results available within approximately 30 minutes. The differentiated technical value proposition versus bacteriological culture methods is the ability to quantify the metabolic activity of both aerobic and anaerobic populations — including wall-associated microflora — without requiring native cultivation conditions and with claimed superior sensitivity and specificity. The IP estate comprises 8 registered patents spanning SCFA separation, encephalopathy differential diagnosis, hepatic encephalopathy drug selection, bile acid and cholesterol metabolism assessment, oral cavity microflora determination and treatment, and vaginal microflora determination and treatment. Methodological manuals covering gastroenterology, dentistry, gynecology, pediatrics, and coloproctology extend the application surface across clinical specialties.

Uni-Med operates three documented revenue streams: (1) laboratory diagnostic services where partner laboratories forward samples to Uni-Med for processing, (2) sale of complete research kits — including sample-preparation equipment (centrifuges, pipettes, freezers), chromatography hardware, and software — to laboratories that wish to run the assay themselves, and (3) technology licensing and cooperation arrangements in which Uni-Med's registered medical technology is licensed to medical laboratories, including a joint assembly arrangement with Chemanalitservice LLC in Dzerzhinsk. Distribution is exclusively domestic (Russia), the company employs approximately 12 people, and no revenue, funding, ownership structure, or management team information is publicly disclosed.

Name

Uni-Med LLC

Legal name

OOO «Уни-мед» (Общество с ограниченной ответственностью «Уни-мед»)

Website

https://uni-med.ru

Company type

Private

Operating status

Operating

Headcount range

11–50 employees

Short description

Uni-Med LLC is a Moscow-based Russian medical laboratory that provides biochemical microbiome diagnostic services using proprietary gas-liquid chromatography to detect short-chain fatty acids in stool and saliva, serving gastroenterology and dental patients via a nationwide network of partner laboratories.

Ownership category

akta.pro rank

Headquarters

HQ city

Moscow

HQ country

Russia

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales

Revenue model

1. Laboratory Diagnostic Services: Uni-Med operates as a medical laboratory providing biochemical diagnostic services for assessing microbiome status in patients. The company processes samples from partner laboratories and medical institutions.
2. Research Equipment and Kit Sales: Sale of complete research kits for studying short-chain fatty acids to partner laboratories. The kits include equipment for sample preparation (centrifuges, pipettes, tubes), chromatography equipment, and software.
3. Technology Licensing and Cooperation: Licensing of proprietary medical technology to medical laboratories for conducting microbiome analysis. The company collaborates with laboratories to implement their medical technology for analyzing metabolic activity of intestinal and oral microbiota.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels2 records

Core offering

Uni-Med LLC is a medical laboratory providing biochemical diagnostic services based on short-chain fatty acid (SCFA) analysis using gas-liquid chromatography. Its core offerings are the biochemical express analysis of stool for intestinal dysbiosis assessment (results within one hour) and the biochemical express analysis of oral fluid for oral microbiome assessment (results within 30 minutes). The company also sells complete research kits and software packages to partner laboratories and licenses its proprietary SCFA detection technology to other medical laboratories.

Product overview

Uni-Med LLC is a medical laboratory offering biochemical diagnostic services based on short-chain fatty acid (SCFA) analysis using gas-liquid chromatography. The core product is the biochemical express analysis of stool for dysbiosis assessment, complemented by biochemical express analysis of oral fluid for oral microbiome evaluation. These services are supported by research kits for laboratory implementation and methodology manuals for various clinical applications in gastroenterology, dentistry, gynecology, pediatrics, and coloproctology. All diagnostic methods are protected by 8 patents and registered as medical technologies (Registration Certificate FS-2006/030-y).

Differentiator

Problem solved

Functional benefit

Products and services

• Biochemical Express Fecal Analysis for Dysbiosis (Биохимический экспресс-анализ кала на дисбактериоз) Biochemical express test of stool for dysbiosis assessment using gas-liquid chromatography to analyze short-chain fatty acids (C2-C6 fraction with isomers), providing rapid evaluation of gut microbiome metabolic activity within one hour. Intended for patients with gastrointestinal disorders and clinical decision-makers (gastroenterologists, lab physicians).
• Biochemical Express Saliva Analysis for Oral Microbiome (Биохимический экспресс-анализ ротовой жидкости) Biochemical express analysis of oral fluid (saliva) for assessing oral microbiome status by determining short-chain fatty acid metabolites using GLC chromatography, completed in 30 minutes. Targets patients with gingivitis, periodontitis, dental caries, and pre-implant evaluation needs.
• SCFA Research Kits (Комплекты для исследований КЖК) Complete research kits for short-chain fatty acid analysis sold to medical laboratories, containing sample preparation equipment (furniture, freezers, centrifuges, pipettes, tubes), chromatography equipment (chromatograph, capillary column, microsyringe, gas generators), and software, enabling laboratory implementation of the medical technology.
• Microbiome Analysis Technology Licensing Licensing of Uni-Med's proprietary registered medical technology (FS-2006/030-u) to partner medical laboratories for conducting microbiome analysis of intestinal and oral microbiota. Delivered as complete equipment and software packages with integration support from Chemanalitservice LLC.

Named customers2 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Seven partnerships are on record, tiered core and minor.

• Chromos (Хромос)coreTechnology or IntegrationPartnership for development and production of chromatographs. Chromos provides chromatography equipment necessary for implementing Uni-Med's gas-liquid chromatography-based microbiome analysis technology.
• Moscow City Oncology Hospital №62coreStrategic or Co-development PartnerCollaboration with leading oncology hospital for clinical research and development of diagnostic applications for microbiome analysis in oncological contexts.
• Ratiopharm RUminorStrategic or Co-development PartnerPartnership with pharmaceutical company for development of pharmaceutical preparation selection methods based on microbiome analysis.
• Donetsk State UniversitycoreStrategic or Co-development PartnerAcademic partnership for scientific research in microbiome analysis and biochemical diagnostic methods development.
• Bifilux (Бифилюкс)minorStrategic or Co-development PartnerPartnership with probiotic/prebiotic company for research on intestinal microbiome correction methods.
• Dr. Falk Pharma Representative OfficeminorStrategic or Co-development PartnerPartnership with German pharmaceutical company specializing in gastroenterology medications for research on treatment selection methods.
• Chemanalitservice LLC (Химаналитсервис), Dzerzhinsk, Nizhny Novgorod RegioncoreTechnology or IntegrationJoint assembly of equipment kits and software packages for implementing microbiome analysis technology in medical laboratories. Chemanalitservice provides equipment integration services for deploying Uni-Med's diagnostic technology.

Scale indicators3 records

Recent moves6 records

Expansion highlights3 records

Regional players

• KDL: Russian clinical laboratory network and Uni-Med distribution partner. Comparable as a regional diagnostic provider serving similar patient and clinician customers across Russia.
• Helix Laboratory Services: Major Russian diagnostic laboratory network and Uni-Med channel partner. Comparable from a customer-base and geography perspective, though Helix offers broad routine testing while Uni-Med provides the specialty microbiome assay distributed through its network.
• Gemotest: Russian laboratory network and Uni-Med partner. Comparable as a regional diagnostic lab competitor with overlapping patient populations; also functions as a commercial channel for Uni-Med's biochemical express dysbiosis testing.
• Citilab: Russian diagnostic laboratory chain and Uni-Med partner. Operates in the same Moscow-headquartered regional lab category and offers comparable patient access points for specialty testing.
• INVITRO: Russia's largest private medical laboratory network. Operates in the same Russian patient access channel as Uni-Med's distribution partners; offers a broader general-diagnostics menu but is the dominant commercial lab competitor in the regions where Uni-Med's specialty test is ordered.

Direct peers

• Diagnostic Solutions Laboratory: US clinical lab offering GI-MAP stool DNA testing and microbiome profiling. Comparable clinical positioning—specialty GI diagnostics sold through clinicians with multiple-indication extensions—even though molecular rather than chromatography-based.
• Genova Diagnostics: US specialty diagnostics laboratory offering CDSA stool profiles and metabolomic GI assessments to clinicians worldwide. Direct competitor in the functional medicine microbiome testing space where Uni-Med's chromatography-based SCFA analysis competes with stool metabolomics panels.
• Doctor's Data: US clinical laboratory specializing in comprehensive stool analysis and microbiome assessment using chromatography and culture methods. Most directly comparable to Uni-Med in test philosophy (functional/metabolomic readouts) and customer base (functional/integrative medicine practitioners).

Others

• BioGaia: Swedish probiotics company that partners with Uni-Med on microbiome correction research. Comparable as a microbiome-focused commercial entity; positioned as an enabling partner rather than direct competitor given its therapeutics/supplements orientation.

Emerging players

• Viome: US-based direct-to-consumer microbiome testing company using metatranscriptomic sequencing. Conceptually comparable as a functional microbiome health-assessment service, though it competes upstream of Uni-Med's physician-ordered clinical testing channel.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

• LinkedInlinkedin.com/company/uni-med-llc

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Uni-Med LLC